Expression of biomarkers modulating prostate cancer progression: Implications in the treatment of the disease

Giuseppe Di Lorenzo, S. De Placido, R. Autorino, M. De Laurentiis, C. Mignogna, M. D'Armiento, G. Tortora, G. De Rosa, M. D'Armiento, M. De Sio, A. R. Bianco, F. P. D'Armiento

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Objectives: To determine whether COX-2, bcl-2 and neoangiogenesis are related to human prostate cancer relapse after definitive surgical treatment and progression toward androgen independence and to evaluate the association between the patterns of these tumoral biomarkers and other standard clinico-pathological parameters (such as Gleason score, PSA, TNM stage). Materials and methods: We retrospectively analyzed the records on 126 prostate cancer samples from patients treated at our University Hospital from 1995 to 2002. The 72 patients with clinically localized disease (group 1) had undergone radical prostatectomy. Another 54 patients (group 2) had metastatic androgen-independent disease. Archived material relating to the subjects was then immunostained for bcl-2, COX-2 and CD-31, using an anti-bcl-2 monoclonal primary antibody, an anti-COX-2 polyclonal rabbit antibody and an anti-CD-31 monoclonal mouse antibody to evaluate neoangiogenesis (MVD, microvessel density). Results: We found that bcl-2, COX-2 and MVD expression increased from group 1 to group 2. The intergroup difference was significant only for high MVD (P

Original languageEnglish
Pages (from-to)54-59
Number of pages6
JournalProstate Cancer and Prostatic Diseases
Volume8
Issue number1
DOIs
Publication statusPublished - Mar 2005

Fingerprint

Microvessels
Prostatic Neoplasms
Biomarkers
Androgens
Monoclonal Antibodies
Neoplasm Grading
Prostatectomy
Anti-Idiotypic Antibodies
Therapeutics
Rabbits
Recurrence

Keywords

  • Bcl-2
  • COX-2
  • MVD
  • Prognostic factors

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Expression of biomarkers modulating prostate cancer progression : Implications in the treatment of the disease. / Di Lorenzo, Giuseppe; De Placido, S.; Autorino, R.; De Laurentiis, M.; Mignogna, C.; D'Armiento, M.; Tortora, G.; De Rosa, G.; D'Armiento, M.; De Sio, M.; Bianco, A. R.; D'Armiento, F. P.

In: Prostate Cancer and Prostatic Diseases, Vol. 8, No. 1, 03.2005, p. 54-59.

Research output: Contribution to journalArticle

Di Lorenzo, G, De Placido, S, Autorino, R, De Laurentiis, M, Mignogna, C, D'Armiento, M, Tortora, G, De Rosa, G, D'Armiento, M, De Sio, M, Bianco, AR & D'Armiento, FP 2005, 'Expression of biomarkers modulating prostate cancer progression: Implications in the treatment of the disease', Prostate Cancer and Prostatic Diseases, vol. 8, no. 1, pp. 54-59. https://doi.org/10.1038/sj.pcan.4500768
Di Lorenzo, Giuseppe ; De Placido, S. ; Autorino, R. ; De Laurentiis, M. ; Mignogna, C. ; D'Armiento, M. ; Tortora, G. ; De Rosa, G. ; D'Armiento, M. ; De Sio, M. ; Bianco, A. R. ; D'Armiento, F. P. / Expression of biomarkers modulating prostate cancer progression : Implications in the treatment of the disease. In: Prostate Cancer and Prostatic Diseases. 2005 ; Vol. 8, No. 1. pp. 54-59.
@article{28292081583c4a1ba1b9d472d7f093f6,
title = "Expression of biomarkers modulating prostate cancer progression: Implications in the treatment of the disease",
abstract = "Objectives: To determine whether COX-2, bcl-2 and neoangiogenesis are related to human prostate cancer relapse after definitive surgical treatment and progression toward androgen independence and to evaluate the association between the patterns of these tumoral biomarkers and other standard clinico-pathological parameters (such as Gleason score, PSA, TNM stage). Materials and methods: We retrospectively analyzed the records on 126 prostate cancer samples from patients treated at our University Hospital from 1995 to 2002. The 72 patients with clinically localized disease (group 1) had undergone radical prostatectomy. Another 54 patients (group 2) had metastatic androgen-independent disease. Archived material relating to the subjects was then immunostained for bcl-2, COX-2 and CD-31, using an anti-bcl-2 monoclonal primary antibody, an anti-COX-2 polyclonal rabbit antibody and an anti-CD-31 monoclonal mouse antibody to evaluate neoangiogenesis (MVD, microvessel density). Results: We found that bcl-2, COX-2 and MVD expression increased from group 1 to group 2. The intergroup difference was significant only for high MVD (P",
keywords = "Bcl-2, COX-2, MVD, Prognostic factors",
author = "{Di Lorenzo}, Giuseppe and {De Placido}, S. and R. Autorino and {De Laurentiis}, M. and C. Mignogna and M. D'Armiento and G. Tortora and {De Rosa}, G. and M. D'Armiento and {De Sio}, M. and Bianco, {A. R.} and D'Armiento, {F. P.}",
year = "2005",
month = "3",
doi = "10.1038/sj.pcan.4500768",
language = "English",
volume = "8",
pages = "54--59",
journal = "Prostate Cancer and Prostatic Diseases",
issn = "1365-7852",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Expression of biomarkers modulating prostate cancer progression

T2 - Implications in the treatment of the disease

AU - Di Lorenzo, Giuseppe

AU - De Placido, S.

AU - Autorino, R.

AU - De Laurentiis, M.

AU - Mignogna, C.

AU - D'Armiento, M.

AU - Tortora, G.

AU - De Rosa, G.

AU - D'Armiento, M.

AU - De Sio, M.

AU - Bianco, A. R.

AU - D'Armiento, F. P.

PY - 2005/3

Y1 - 2005/3

N2 - Objectives: To determine whether COX-2, bcl-2 and neoangiogenesis are related to human prostate cancer relapse after definitive surgical treatment and progression toward androgen independence and to evaluate the association between the patterns of these tumoral biomarkers and other standard clinico-pathological parameters (such as Gleason score, PSA, TNM stage). Materials and methods: We retrospectively analyzed the records on 126 prostate cancer samples from patients treated at our University Hospital from 1995 to 2002. The 72 patients with clinically localized disease (group 1) had undergone radical prostatectomy. Another 54 patients (group 2) had metastatic androgen-independent disease. Archived material relating to the subjects was then immunostained for bcl-2, COX-2 and CD-31, using an anti-bcl-2 monoclonal primary antibody, an anti-COX-2 polyclonal rabbit antibody and an anti-CD-31 monoclonal mouse antibody to evaluate neoangiogenesis (MVD, microvessel density). Results: We found that bcl-2, COX-2 and MVD expression increased from group 1 to group 2. The intergroup difference was significant only for high MVD (P

AB - Objectives: To determine whether COX-2, bcl-2 and neoangiogenesis are related to human prostate cancer relapse after definitive surgical treatment and progression toward androgen independence and to evaluate the association between the patterns of these tumoral biomarkers and other standard clinico-pathological parameters (such as Gleason score, PSA, TNM stage). Materials and methods: We retrospectively analyzed the records on 126 prostate cancer samples from patients treated at our University Hospital from 1995 to 2002. The 72 patients with clinically localized disease (group 1) had undergone radical prostatectomy. Another 54 patients (group 2) had metastatic androgen-independent disease. Archived material relating to the subjects was then immunostained for bcl-2, COX-2 and CD-31, using an anti-bcl-2 monoclonal primary antibody, an anti-COX-2 polyclonal rabbit antibody and an anti-CD-31 monoclonal mouse antibody to evaluate neoangiogenesis (MVD, microvessel density). Results: We found that bcl-2, COX-2 and MVD expression increased from group 1 to group 2. The intergroup difference was significant only for high MVD (P

KW - Bcl-2

KW - COX-2

KW - MVD

KW - Prognostic factors

UR - http://www.scopus.com/inward/record.url?scp=20444504317&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20444504317&partnerID=8YFLogxK

U2 - 10.1038/sj.pcan.4500768

DO - 10.1038/sj.pcan.4500768

M3 - Article

C2 - 15655565

AN - SCOPUS:20444504317

VL - 8

SP - 54

EP - 59

JO - Prostate Cancer and Prostatic Diseases

JF - Prostate Cancer and Prostatic Diseases

SN - 1365-7852

IS - 1

ER -